Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Ghigo

Showing results (261-270 of 455) with videos related to

Pageof 46
Sort By:
The Journal of Clinical Endocrinology and Metabolism|April 1, 1995
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during pubertyJ Bellone, G Aimaretti, E Bartolotta, et al.
Journal of Endocrinological Investigation|March 10, 2005
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?R Cozzi, R Attanasio, S Grottoli, et al.
Neuroendocrinology|January 1, 1986
Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjectsF Massara, E Ghigo, K Demislis, et al.
The Journal of Clinical Endocrinology and Metabolism|November 4, 2000
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humansL Gianotti, M Maccario, F Lanfranco, et al.
European Journal of Endocrinology|October 1, 1996
Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human agingE Ghigo, E Arvat, L Gianotti, et al.
Journal of Endocrinological Investigation|March 4, 2000
DHEA-S levels in hypopituitaric patients with severe GH deficiency are strongly reduced across lifespan. Comparison with IGF-I levels before and during rhGH replacementG Aimaretti, C Baffoni, M R Ambrosio, et al.
Journal of Endocrinological Investigation|March 10, 2005
Cost-of-illness study in acromegalic patients in ItalyG Didoni, S Grottol, V Gasco, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 1998
Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenomaE Arvat, R Giordano, J Ramunni, et al.
Journal of Endocrinological Investigation|April 4, 2002
Activity of GH/IGF-1 axis in burn patients: comparison with normal subjects and patients with GH deficiencyL Gianotti, M Stella, D Bollero, et al.
Journal of Endocrinological Investigation|February 10, 2010
A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group CareM Trento, C Kucich, P Tibaldi, et al.
Pageof 46

Showing results (261-270 of 455) with videos related to

Sort By:
Pageof 46
The Journal of Clinical Endocrinology and Metabolism|April 1, 1995
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during pubertyJ Bellone, G Aimaretti, E Bartolotta, et al.
Journal of Endocrinological Investigation|March 10, 2005
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?R Cozzi, R Attanasio, S Grottoli, et al.
Neuroendocrinology|January 1, 1986
Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjectsF Massara, E Ghigo, K Demislis, et al.
The Journal of Clinical Endocrinology and Metabolism|November 4, 2000
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humansL Gianotti, M Maccario, F Lanfranco, et al.
European Journal of Endocrinology|October 1, 1996
Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human agingE Ghigo, E Arvat, L Gianotti, et al.
Journal of Endocrinological Investigation|March 4, 2000
DHEA-S levels in hypopituitaric patients with severe GH deficiency are strongly reduced across lifespan. Comparison with IGF-I levels before and during rhGH replacementG Aimaretti, C Baffoni, M R Ambrosio, et al.
Journal of Endocrinological Investigation|March 10, 2005
Cost-of-illness study in acromegalic patients in ItalyG Didoni, S Grottol, V Gasco, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 1998
Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenomaE Arvat, R Giordano, J Ramunni, et al.
Journal of Endocrinological Investigation|April 4, 2002
Activity of GH/IGF-1 axis in burn patients: comparison with normal subjects and patients with GH deficiencyL Gianotti, M Stella, D Bollero, et al.
Journal of Endocrinological Investigation|February 10, 2010
A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group CareM Trento, C Kucich, P Tibaldi, et al.
Pageof 46